Connie B. Newman, MD, FACP, FAMWA
Connie B. Newman, MD, FACP, FAMWA, a graduate of Weill Cornell Medical College and Wellesley College, is a Board-certified endocrinologist, Adjunct Associate Professor of Medicine at New York University School of Medicine, and Academic Visitor, University of Oxford, Oxford UK. She has expertise in the management of lipid disorders and diabetes, statin safety, and large randomized clinical trials. She is a member of the Cholesterol Treatment Trialists Collaboration which conducts meta-analyses of individual patient data from the large statin cardiovascular outcome trials. Dr. Newman has written several papers on statin safety and tolerability, and was a co-author of the 2015 European Atherosclerosis Society Consensus Statement, Statin Associated Muscle Symptoms: Impact on Statin Therapy.
Dr. Newman is a member of the AMWA Board of Directors (2015-17). She leads the obesity initiatives for the AMWA Preventive Medicine Task Force, and is a liaison to the STOP Obesity Alliance, the Advisory Council of the Obesity Action Fund, National Obesity Care Week 2015, and the National Forum for Heart Disease and Stroke Prevention. She co-chairs the AMWA Editorial Committee, the AMWA Fellowship Committee, and AWHS. She is also active in the Endocrine Society, where she chairs the Special Programs Committee, and in the American Heart Association, where she is a member of the Women’s Leadership Committee of the ATVB Council and the Clinical Lipidology Committee. She is committed to improving public health through research, education, and disease prevention.
